317 related articles for article (PubMed ID: 38166953)
1. Helicobacter pylori infection and Parkinson's Disease: etiology, pathogenesis and levodopa bioavailability.
Wei BR; Zhao YJ; Cheng YF; Huang C; Zhang F
Immun Ageing; 2024 Jan; 21(1):1. PubMed ID: 38166953
[TBL] [Abstract][Full Text] [Related]
2. Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
Nyholm D; Hellström PM
J Parkinsons Dis; 2021; 11(1):61-69. PubMed ID: 33164946
[TBL] [Abstract][Full Text] [Related]
3. The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease.
Justich MB; Rojas OL; Fasano A
Semin Neurol; 2023 Aug; 43(4):553-561. PubMed ID: 37562451
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
van Kessel SP; Bullock A; van Dijk G; El Aidy S
mSystems; 2022 Feb; 7(1):e0119121. PubMed ID: 35076270
[TBL] [Abstract][Full Text] [Related]
5. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease.
McGee DJ; Lu XH; Disbrow EA
J Parkinsons Dis; 2018; 8(3):367-374. PubMed ID: 29966206
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori eradication for Parkinson's disease.
Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
Leta V; Klingelhoefer L; Longardner K; Campagnolo M; Levent HÇ; Aureli F; Metta V; Bhidayasiri R; Chung-Faye G; Falup-Pecurariu C; Stocchi F; Jenner P; Warnecke T; Ray Chaudhuri K;
Eur J Neurol; 2023 May; 30(5):1465-1480. PubMed ID: 36757008
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
Pfeiffer RF; Isaacson SH; Pahwa R
Parkinsonism Relat Disord; 2020 Jul; 76():63-71. PubMed ID: 32461054
[TBL] [Abstract][Full Text] [Related]
9. The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
Menozzi E; Schapira AHV
CNS Drugs; 2024 May; 38(5):315-331. PubMed ID: 38570412
[TBL] [Abstract][Full Text] [Related]
10. Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease.
Hasuike Y; Endo T; Koroyasu M; Matsui M; Mori C; Yamadera M; Fujimura H; Sakoda S
Med Hypotheses; 2020 Jan; 134():109436. PubMed ID: 31678900
[TBL] [Abstract][Full Text] [Related]
11. Brain-gut-microbiota axis in Parkinson's disease.
Mulak A; Bonaz B
World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
[TBL] [Abstract][Full Text] [Related]
12. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease.
Dănău A; Dumitrescu L; Lefter A; Tulbă D; Popescu BO
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769091
[TBL] [Abstract][Full Text] [Related]
13. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease.
van Kessel SP; El Aidy S
Front Neurol; 2019; 10():1087. PubMed ID: 31681153
[TBL] [Abstract][Full Text] [Related]
14. A review of studies on gut microbiota and levodopa metabolism.
Zhong Z; Ye M; Yan F
Front Neurol; 2023; 14():1046910. PubMed ID: 37332996
[TBL] [Abstract][Full Text] [Related]
15. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-
Zhao Z; Li F; Ning J; Peng R; Shang J; Liu H; Shang M; Bao XQ; Zhang D
Acta Pharm Sin B; 2021 Sep; 11(9):2859-2879. PubMed ID: 34589401
[TBL] [Abstract][Full Text] [Related]
16. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
Lyte M
Med Hypotheses; 2010 May; 74(5):895-7. PubMed ID: 19962247
[TBL] [Abstract][Full Text] [Related]
17. The role of small intestinal bacterial overgrowth in Parkinson's disease.
Fasano A; Bove F; Gabrielli M; Petracca M; Zocco MA; Ragazzoni E; Barbaro F; Piano C; Fortuna S; Tortora A; Di Giacopo R; Campanale M; Gigante G; Lauritano EC; Navarra P; Marconi S; Gasbarrini A; Bentivoglio AR
Mov Disord; 2013 Aug; 28(9):1241-9. PubMed ID: 23712625
[TBL] [Abstract][Full Text] [Related]
18. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Inflammatory Cytokine and Anti
Shamsdin SA; Khazraei H; Rahimi Jaberi A; Zamani M; Rafiee Monjezi M
Middle East J Dig Dis; 2022 Jan; 14(1):96-102. PubMed ID: 36619735
[No Abstract] [Full Text] [Related]
20. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
